Memorial Sloan Kettering Cancer Center
ES-SCLC 2020 Update: Which IO Options Showed Activity in Phase III Trials? How Effective Is Lurbinectedin in Stage IV Disease Progressed After 1L Therapy?
By
Nebraska Oncology Society
FEATURING
Gregory Riely
By
Nebraska Oncology Society
FEATURING
Gregory Riely
Login to view comments.
Click here to Login